Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease

Interstitial lung disease (ILD) is a common pulmonary manifestation in chronic tissue diseases (CTD), significantly affecting patient's prognosis.

The main purpose of this study is to evaluate the efficacy of telitacicept compared with placebo in slowing down the decline in lung volume in patients with interstitial lung disease associated with connective tissue disease (CTD-ILD) on the basis of standard treatment.

Study Overview

• Status: Not yet recruiting
• Conditions: CTD-ILD
• Intervention / Treatment: Drug: Telitacicept; Drug: Placebo

• Study Type: Interventional
• Enrollment (Estimated): 260
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Mengtao Li; Phone Number: +86-10-69158354; Email: Mengtao.li@cstar.org.cn
• Study Contact Backup: Name: Qian Wang; Phone Number: +86-10-69158354; Email: Zhengaqian@126.com

Study Locations

• China
  • Beijing Municipality
    • Beijing, Beijing Municipality, China, 100000
      • Peking Union Medical College Hospital
      • Contact: Mengtao Li; Phone Number: 86-10-69154186; Email: Mengtao.li@cstar.org.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Voluntary informed consent provided;
2. Male or female aged ≥ 18 years old;
3. Documented diagnosis of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy (IIM), Sjogren's syndrome (SjD) , Systemic sclerosis（SSc）,or mixed connective tissue disease (MCTD) in accordance with internationally recognized classification criteria;
4. Diagnosis of ILD on High Resolution Computed Tomography (HRCT) with disease extent of greater than or equal to (≥) 10% of the whole lung (WL-ILD);
5. During screening, FVC%Pred ≥ 45%;
6. During screening, DLCO%Pred(corrected for hemoglobin) ≥ 30%;
7. Stable standard treatment was received before randomization to control ILD and/or connective tissue disease;

Exclusion Criteria:

1. Diagnosis of Interstitial lung disease other than CTD-ILD;
2. ILD progresses rapidly within 12 weeks before screening or during screening;
3. During screening, HRCT showed severe emphysema (the degree of emphysema exceeded that of ILD);
4. Obstructive pulmonary disease (pre-bronchodilator Forced Expiratory Volume (FEV1) /FVC <0.7);
5. Pulmonary arterial hypertension requiring therapy, as determined by the investigator;
6. Having diffuse alveolar hemorrhage (DAH) or other pulmonary conditions that may have confounding effects, as well as related signs or symptoms;
7. Unable to complete the pulmonary function test, or requiring supplementary oxygen supply;
8. Clinically significant laboratory abnormalities;
9. QTc interval prolongation on ECG;
10. Allergy to human or mouse-derived biological products, or history of other drug allergies, and the investigator deems that the patient is not eligible to participate.

11. Previous treatments received:

    • Previous or planned organ transplantation or bone marrow transplantation;
    • Plasma exchange or extracorporeal light separation exchange was performed within 6 months before randomization, or a plasma filtration device was used;
    • Any targeted BLyS or APRIL drug treatment was received within 12 weeks before randomization;
    • Biologic therapy was received within 12 weeks or within 5 half-lives of the corresponding drug (whichever is longer) before randomization;
    • B-cell depletion drugs were used within 6 months before randomization;
    • Non-biological systemic immunosuppressive drugs other than standard treatment were used within 4 weeks before randomization;
    • Anti-fibrotic drugs were used within 4 weeks before randomization;
    • Cyclophosphamide treatment was received within 6 months before randomization;
    • Cytotoxic drugs were used within 6 months before randomization;
    • Intravenous or intramuscular glucocorticoids were used within 4 weeks before randomization;
12. Major surgery within 12 weeks prior to screening or planned during the duration of the study；
13. Received or plan to receive any live vaccine within 28 days prior to randomization;
14. Participation in any clinical trial 28 days prior to randomization or within 5 times the half-life of an investigational drug (whichever is longer);
15. has active hepatitis or a history of severe liver disease；
16. Acute or chronic infection requiring treatment;
17. suffered from symptomatic herpes zoster within 12 weeks prior to screening;
18. Active tuberculosis；
19. HIV infection;
20. History of malignant tumors；
21. Significant cardiovascular disease, liver, kidney, respiratory, endocrine or hematologic disease, or other medical conditions that, in the opinion of the investigator, would preclude the subject's participation in the study or require hospitalization during the trial;
22. History of drug or alcohol abuse or dependence；
23. Pregnant or lactating women, and those intending to become pregnant during the trial;
24. Patients considered unsuitable by the investigator to participate in the trial ;

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo; Participants will receive placebo in addition to standard therapy.	Drug: Placebo; The placebo contains no active ingredients. To maintain the blind, the placebo matches the active drug in all physical aspects.
Experimental: Telitacicept; Participants will receive elitacicept in addition to standard therapy.	Drug: Telitacicept; Subjects will receive Telitacicept.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Change from Baseline in FVC(mL) at Week 52	Baseline and Week 52

Secondary Outcome Measures

Outcome Measure	Time Frame
Change from Baseline in FVC%Pred at Week 52	Baseline and Week 52
Change from Baseline in DLCO%Pred at Week 52	Baseline and Week 52
Time to ILD Progression or Death	The time from Baseline to Week 52
Change from Baseline in Quantitative Interstitial Lung Disease in the Whole Lung (QILD-WL) At Week 52	Baseline and Week 52
Change from Baseline in Quantitative Measures of Lung Fibrosis (QLF) in the Whole Lung At Week 52	Baseline and Week 52
the proportion of subjects with a QILD-WL score reduction ≥2% at week 52	Baseline and Week 52
The proportion of subjects who showed a ≥5% decrease in FVC (mL) from baseline at week 52;	Baseline and Week 52
The proportion of subjects who showed a ≥10% decrease in FVC (mL) from baseline at week 52;	Baseline and Week 52
Change from Baseline in the short form health survey（SF-36） at Week 52	Baseline and Week 52
Change from Baseline in Patient global impression of severity（PGI-S） at Week 52	Baseline and Week 52
Changes from baseline in immunological markers（IgG、IgA、IgM、CD19+ B）at Week 52	Baseline and Week 52
Incidence and severity of adverse events	From signing of informed consent until 4 weeks after the last dose.

Collaborators and Investigators

• Sponsor: RemeGen Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Estimated): April 20, 2026
• Primary Completion (Estimated): May 31, 2029
• Study Completion (Estimated): May 31, 2030

Study Registration Dates

• First Submitted: March 9, 2026
• First Submitted That Met QC Criteria: March 22, 2026
• First Posted (Actual): March 27, 2026

Study Record Updates

• Last Update Posted (Actual): April 9, 2026
• Last Update Submitted That Met QC Criteria: April 6, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: telitacicept
• Other Study ID Numbers: RC18-C309

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No